bioAffinity Technologies Files 8-K

TL;DR

BIAF filed an 8-K on 9/29/25 for a material agreement and other events.

AI Summary

On September 29, 2025, bioAffinity Technologies, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The exact nature of the agreement and the financial details are not specified in this filing.

Why It Matters

This 8-K filing indicates significant corporate activity for bioAffinity Technologies, Inc., potentially involving new agreements or financial updates that could impact its business operations and stock.

Risk Assessment

Risk Level: medium — The filing of an 8-K often signals material events, but the lack of specific details in this summary requires caution.

Key Players & Entities

• bioAffinity Technologies, Inc. (company) — Registrant
• September 29, 2025 (date) — Earliest event reported

FAQ

Key Financial Figures

• $0.007 — he "Shares") of common stock, par value $0.007 per share (the "Common Stock") and (ii)
• $2.50 — was sold at a public offering price of $2.50. Each Pre-Funded Warrant was sold at a
• $2.493 — was sold at a public offering price of $2.493. The aggregate gross proceeds from th
• $4.8 m — eds from the Offering was approximately $4.8 million, before deducting placement agent
• $120,000 — ring and reimbursed the Placement Agent $120,000 for its expenses in connection with the
• $1.00 — maintain a minimum closing bid price of $1.00 ("Minimum Bid Price Requirement") per s
• $1,439,404 — t") because its stockholders' equity of $1,439,404 as of March 31, 2025, as reported in th
• $2,500,000 — 5, was below the minimum requirement of $2,500,000. Pursuant to Nasdaq's Listing Rules, th
• $1.2 million — roceeds to the Company of approximately $1.2 million. As previously reported in a Current
• $4 million — is expected to eliminate approximately $4 million in warrant-related derivate liabilities
• $2.8 million — n stockholders' equity of approximately $2.8 million. In addition, since the filing of the C
• $1.3 million — the Company has received approximately $1.3 million from the exercise of outstanding warran

Filing Documents

• form8-k.htm (8-K) — 64KB
• ex1-1.htm (EX-1.1) — 146KB
• ex4-1.htm (EX-4.1) — 113KB
• ex10-1.htm (EX-10.1) — 241KB
• ex99-1.htm (EX-99.1) — 14KB
• ex99-2.htm (EX-99.2) — 14KB
• ex99-1_001.jpg (GRAPHIC) — 19KB
• ex99-1_002.jpg (GRAPHIC) — 9KB
• ex99-2_001.jpg (GRAPHIC) — 6KB
• ex99-2_002.jpg (GRAPHIC) — 5KB
• 0001493152-25-016366.txt ( ) — 977KB
• biaf-20250929.xsd (EX-101.SCH) — 4KB
• biaf-20250929_def.xml (EX-101.DEF) — 26KB
• biaf-20250929_lab.xml (EX-101.LAB) — 36KB
• biaf-20250929_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 30, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -5-

View Full Filing

View this 8-K filing on SEC EDGAR